The protective effectiveness of natural rotavirus infection in an American Indian population

J Infect Dis. 1998 Dec;178(6):1562-6. doi: 10.1086/314504.


The degree of protection conferred by natural rotavirus infection was estimated through analyses of data gathered as part of a 2-year rotavirus vaccine study of 1185 Native American infants. In 292 placebo recipients with complete serum sample sets, rotavirus IgA antibody indicative of infection before 2 months of age was associated with a 58% decrease in symptomatic infections throughout the trial. In all 391 placebo recipients, the preventive effectiveness of an initial symptomatic infection was 72% overall and 94% within 6 months following the infection. In contrast to studies conducted at other sites in the United States, serotype G3 was the predominant serotype associated with gastrointestinal episodes (80%). The effectiveness of an initial serotype G3 episode with respect to preventing subsequent serotype G3 episodes was 91%.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Viral / blood
  • Follow-Up Studies
  • Humans
  • Immunoglobulin A / blood
  • Indians, North American* / statistics & numerical data
  • Infant
  • Infant, Newborn
  • Proportional Hazards Models
  • Risk Factors
  • Rotavirus / immunology
  • Rotavirus Infections / epidemiology*
  • Rotavirus Infections / immunology*
  • Rotavirus Infections / prevention & control
  • Serotyping
  • Time Factors
  • United States / epidemiology
  • Viral Vaccines*


  • Antibodies, Viral
  • Immunoglobulin A
  • Viral Vaccines